Denise Carter Biography and Net Worth

COO of Quoin Pharmaceuticals

Ms. Carter has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. Prior to co-founding Quoin, Ms. Carter held various positions with Innocoll, Inc., including president Innocoll Pharmaceuticals and executive vice president of business development and corporate affairs of Innocoll Inc. She also served as vice president of business development of the drug delivery division of West Pharmaceuticals, and she has held executive positions at Eurand and Fuisz Technologies (Biovail). Ms. Carter earned her MBA from Wharton School of Business, University of Pennsylvania and a B.S. in Chemistry from the College of William and Mary.

What is Denise P. Carter's net worth?: The estimated net worth of Denise P. Carter is at least $177.99 thousand as of August 31st, 2026. Ms. Carter owns 37,709 shares of Quoin Pharmaceuticals stock worth more than $177,986 as of October 7th. This net worth approximation does not reflect any other assets that Ms. Carter may own. Learn More about Denise P. Carter's net worth.
How do I contact Denise P. Carter?: The corporate mailing address for Ms. Carter and other Quoin Pharmaceuticals executives is 23 Hata'as Street, Kfar Saba, 44425. Quoin Pharmaceuticals can also be reached via phone at +97299741444 and via email at [email protected]. Learn More on Denise P. Carter's contact information.
Has Denise P. Carter been buying or selling shares of Quoin Pharmaceuticals?: Denise P. Carter has not been actively trading shares of Quoin Pharmaceuticals within the last three months. Most recently, on Monday, August 31st, Denise P. Carter bought 20,490 shares of Quoin Pharmaceuticals stock. The stock was acquired at an average cost of $4.88 per share, with a total value of $99,991.20. Following the completion of the transaction, the chief operating officer now directly owns 37,709 shares of the company's stock, valued at $184,019.92. Learn More on Denise P. Carter's trading history.
Who are Quoin Pharmaceuticals' active insiders?: Quoin Pharmaceuticals' insider roster includes Denise Carter (COO), and Anthony Culverwell (Director). Learn More on Quoin Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Quoin Pharmaceuticals?: In the last twelve months, Quoin Pharmaceuticals insiders bought shares 5 times. They purchased a total of 72,522 shares worth more than $408,606.08. The most recent insider tranaction occured on August, 31st when COO Denise P. Carter bought 20,490 shares worth more than $99,991.20. Insiders at Quoin Pharmaceuticals own 11.2% of the company. Learn More about insider trades at Quoin Pharmaceuticals.
Information on this page was last updated on 8/31/2026.

Denise P. Carter Insider Trading History at Quoin Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/31/2026	Buy	20,490	$4.88	$99,991.20	37,709
12/23/2024	Buy	15,873	$15.75	$249,999.75	17,218
9/4/2024	Buy	908	$27.30	$24,788.40	1,345

Denise P. Carter Buying and Selling Activity at Quoin Pharmaceuticals

Quoin Pharmaceuticals Company Overview

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Today's Range

Now: $4.62

$4.51

$4.79

50 Day Range

MA: $5.73

$4.26

$7.87

2 Week Range

Now: $4.62

$3.25

$41.80

Volume

3,610 shs

Average Volume

292,420 shs

Market Capitalization

$9.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56